Previous use of statins does not improve the outcome of bloodstream infection after kidney transplantation

Abstract

AbstractPrevious studies have suggested that exposure to statins confers a protective effect in bloodstream infection (BSI) due to the anti‐inflammatory and immunomodulatory properties attributed to these lipid‐lowering drugs. Scarce evidence is available for the solid organ transplant population. Therefore, we compared the time to clinical cure (primary outcome) and the time to fever resolution, new requirement of intensive care unit admission or renal replacement therapy, and 30‐day all‐cause mortality (secondary outcomes) between kidney transplant (KT) recipients with post‐transplant BSI that were receiving or not statin therapy for at least the previous 30 days. We included 80 KT recipients that developed 109 BSI episodes (43 [39.4%] and 66 [60.6%] episodes within the statin and non‐statin groups, respectively). The median interval since the initial prescription to BSI was 512 days (interquartile range [IQR]: 172–1388). Most episodes were of urinary source and due to Enterobacterales. There were no differences in the median time to clinical cure in the statin and non‐statin groups (3.4 [IQR: 3–6.8] versus 4 [IQR: 2–6] days; p‐value = .112). The lack of effect was confirmed by multiple linear regression analysis adjusted for confounding factors (standardized β coefficient = 0.040; p‐value = .709). No significant differences were observed for any of the secondary outcomes either. Vital signs and laboratory values at BSI onset and after 72–96 h were similar in both groups. In conclusion, previous statin therapy had no apparent protective effect on the outcome of post‐transplant BSI among KT recipients. image